ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Homocysteine-induced bone formation dysfunction reversed by icariin via the AKT/FOXO1 signaling pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated homocysteine (Hcy) is an independent osteoporosis (OP) risk factor via oxidative stress-induced bone formation dysfunction. Icariin (ICA) has ethnopharmacological bone-protective effects, but its mechanism against Hcy-induced damage remains unclear. This study aimed to confirm Hcy's causal role in OP and clarify ICA's reversal effect via the AKT/FOXO1 pathway. Mendelian randomization (MR) analyzed Hcy-OP causality. In vitro, Hcy-treated MC3T3-E1 cells (osteoblast model) were evaluated via CCK-8, ALP/alizarin red staining, MDA/SOD detection, and Western blot. Network pharmacology/molecular docking predicted key targets; PI3K inhibitor LY294002 verified the AKT pathway. In vivo, dexamethasone-induced OP mice were assessed via micro-CT, ELISA, HE staining, and Western blot/qPCR. MR confirmed elevated Hcy as an upstream OP risk factor. Hcy inhibited osteoblast function, while ICA reversed this by enhancing proliferation/differentiation (elevated ALP, osteogenic markers: BMP2/COL1/OPG/RUNX2), reducing oxidative stress (lower MDA, higher SOD), and activating AKT/FOXO1 via phosphorylation. In OP mice, ICA improved BMD/trabecular microarchitecture, elevated P1NP, reduced CTX-1, and upregulated osteogenic pathway markers. Hcy-induced bone formation dysfunction drives OP progression. ICA alleviates oxidative stress and activates AKT/FOXO1 to protect against Hcy-related OP, offering a potential therapeutic strategy.
Indexed as
Identifiers
42350823What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.